Atherosclerosis Treatment in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS:

• Patients with stable angina or silent ischemia with angiographically confirmed coronary stenosis >70% (or FFR ≤0.80) unresponsive to optimal medical therapy

• Patients with acute coronary syndrome (NSTEMI or STEMI) requiring urgent PCI or emergent CABG

• Patients with symptomatic carotid stenosis ≥50% (symptomatic) or ≥70% (asymptomatic) per NASCET criteria, eligible for carotid endarterectomy (CEA) or carotid artery stenting (CAS)

• Patients with peripheral arterial disease (PAD) and claudication, rest pain, or CLTI (Rutherford category 3–6) with suitable vascular anatomy for endovascular or open surgical revascularization

• Patients with multi-vessel coronary disease and high SYNTAX Score (>22) who may derive superior outcomes from surgical CABG over PCI

• Patients with familial hypercholesterolemia (LDL >190 mg/dL despite maximal statin therapy) eligible for PCSK9 inhibitor initiation or LDL apheresis

• REQUIRED DIAGNOSTIC WORKUP (Pre-Treatment):

• Fasting lipid panel, HbA1c, high-sensitivity CRP (hsCRP), Lipoprotein(a) [Lp(a)], homocysteine

• 12-lead ECG and ambulatory Holter monitoring

• Transthoracic Echocardiography (TTE) or Transesophageal Echocardiography (TEE) for LV function, wall motion abnormalities, and valvular assessment

• Coronary CT Angiography (CCTA) with calcium scoring (Agatston score) for non-invasive plaque burden assessment

• Invasive coronary angiography (ICA) with FFR/iFR pressure wire study for functional stenosis assessment

• Carotid Doppler ultrasound and/or CTA/MRA for cerebrovascular disease evaluation

• Ankle-Brachial Index (ABI) and peripheral angiography (CTA or invasive) for PAD workup

• Nuclear Myocardial Perfusion Imaging (MPI/SPECT) or Cardiac PET-CT for viability and ischemia quantification in complex cases

• Renal function panel (eGFR, creatinine) prior to contrast administration

• CONTRAINDICATIONS / RELATIVE EXCLUSIONS:

• Active major bleeding or uncorrectable coagulopathy (contraindication to antiplatelet/anticoagulation therapy)

• Severe hepatic dysfunction (precludes statin therapy and most anticoagulants)

• End-stage renal disease requiring dialysis (high contrast nephropathy risk; requires careful planning and pre-hydration protocols)

• Severely calcified, chronically occluded vessels with no viable distal runoff (may preclude endovascular revascularization)

• Prohibitive surgical risk (EuroSCORE II >10–15%) with no suitable catheter-based alternative

• Allergy to iodinated contrast agents not manageable with premedication

• Recent hemorrhagic stroke within 3 months (precludes systemic anticoagulation for ACS management)

PHARMACOLOGICAL MANAGEMENT (Foundation of All Strategies): High-intensity statin therapy (atorvastatin 40–80 mg/day or rosuvastatin 20–40 mg/day) targets LDL-C reduction of ≥50% from baseline, aiming for LDL <55 mg/dL in very-high-risk patients per ESC/ACC guidelines. PCSK9 inhibitors (evolocumab 140 mg SC every 2 weeks or alirocumab 75–150 mg SC every 2 weeks) achieve an additional 50–60% LDL reduction beyond maximally tolerated statin doses and are now standard for FH or post-ACS patients not at goal. Inclisiran (a siRNA targeting PCSK9) offers twice-yearly dosing and is increasingly available in both India and the UAE. Dual antiplatelet therapy (DAPT) with aspirin 75–100 mg plus a P2Y12 inhibitor (ticagrelor 90 mg BID or clopidogrel 75 mg/day) is mandatory post-ACS and post-PCI for 6–12 months. In diabetic patients with established cardiovascular disease, GLP-1 RAs (semaglutide, liraglutide) and SGLT-2 inhibitors (dapagliflozin, empagliflozin) confer independent cardiovascular mortality benefits beyond glycemic control and are incorporated into GDMT.

PERCUTANEOUS CORONARY INTERVENTION (PCI) — Catheter-Based Coronary Revascularization: PCI remains the dominant revascularization strategy for single- and two-vessel coronary disease. Under fluoroscopic and IVUS/OCT guidance, a guide catheter is advanced to the coronary ostium, a 0.014-inch guidewire crosses the stenosis, and the lesion is treated with balloon angioplasty followed by deployment of a Drug-Eluting Stent (DES). Contemporary third-generation DES platforms (Xience Sierra, Synergy bioabsorbable-polymer, Orsiro sirolimus-eluting stent) achieve restenosis rates of <5% at 1 year. Calcified lesions refractory to standard balloon angioplasty are treated with Rotational Atherectomy (Rotablator) or Intravascular Lithotripsy (IVL, Shockwave system) to facilitate stent expansion. For chronic total occlusions (CTO), complex retrograde or antegrade wire escalation techniques are employed by dedicated CTO operators. Fractional Flow Reserve-guided PCI (FFR-guided) is the benchmark standard, avoiding stenting of non-flow-limiting lesions and demonstrably reducing MACE.

CABG — CORONARY ARTERY BYPASS GRAFTING (Surgical Gold Standard for Complex Disease): For patients with three-vessel disease, left main coronary disease, or high SYNTAX Score (>32), CABG provides superior long-term survival and freedom from re-intervention compared to PCI. The procedure uses arterial conduits—Left Internal Mammary Artery (LIMA) anastomosed to the LAD is the cornerstone, with additional grafts using the Right Internal Mammary Artery (RIMA), radial artery, or saphenous vein. Total Arterial Revascularization (TAR) strategies using bilateral mammary arteries improve 10-year patency. Off-Pump CABG (OPCAB) is performed on the beating heart without cardiopulmonary bypass, reducing the risks of cognitive dysfunction, stroke, and renal injury in selected patients. Minimally invasive CABG variants include MIDCAB (Minimally Invasive Direct CABG via mini-thoracotomy) and Totally Endoscopic CABG (TECAB) using robotic assistance (da Vinci Surgical System), both reducing sternal complications and recovery time.

CAROTID REVASCULARIZATION: Carotid Endarterectomy (CEA) remains the gold-standard surgical procedure for significant carotid atherosclerosis, involving surgical plaque excision under regional or general anesthesia with excellent long-term stroke prevention. Carotid Artery Stenting (CAS) with cerebral embolic protection devices (EPDs) is the catheter-based alternative for high-surgical-risk patients. Transcarotid Artery Revascularization (TCAR) combines surgical carotid access with flow reversal and stenting, demonstrating stroke rates comparable to CEA in contemporary registry data.

PERIPHERAL VASCULAR INTERVENTIONS: Endovascular revascularization for PAD includes balloon angioplasty, bare-metal or drug-coated stents (DCS), and drug-coated balloons (DCB, e.g., paclitaxel-coated) for femoropopliteal disease. Atherectomy devices (directional, orbital, laser) debulk calcified plaque prior to angioplasty. For aortoiliac disease, covered stent-grafts (EVAR) or iliac kissing stents provide durable revascularization. Hybrid procedures combining open surgical bypass with endovascular techniques address multilevel disease. For critical limb-threatening ischemia (CLTI), below-the-knee (BTK) revascularization using pedal loop technique or retrograde pedal access prevents major amputation.

EMERGING & ADVANCED THERAPIES: Gene therapy trials targeting PCSK9 (AAV-based) and lipoprotein(a) (pelacarsen, olpasiran RNA interference therapy) are in advanced clinical development. Computed Tomography-derived FFR (CT-FFR, HeartFlow platform) enables non-invasive functional assessment. Photoacoustic imaging and near-infrared spectroscopy (NIRS-IVUS, the LipiScan system) identify vulnerable lipid-rich plaques. Bioresorbable Vascular Scaffolds (BVS), though largely withdrawn from market, continue in research settings.

PHASE 1 — PRE-ARRIVAL & REMOTE CONSULTATION (2–4 Weeks Before Travel):

Patients upload existing medical records, imaging (angiograms, echocardiograms, CT scans), and lab reports to the GAF Healthcare secure patient portal. A GAF-coordinated multidisciplinary team (interventional cardiologist, vascular surgeon, cardiac surgeon) conducts a virtual consultation, reviews diagnostic findings, and proposes a personalized treatment pathway. A formal medical opinion letter, itemized cost estimate, and hospital admission protocol are provided within 48–72 hours. GAF Healthcare initiates e-Medical Visa processing for India or entry documentation for the UAE simultaneously.

PHASE 2 — ARRIVAL & IN-HOSPITAL DIAGNOSTIC WORKUP (Day 1–3):

Upon arrival, a GAF coordinator meets the patient and companion at the airport for transfer to the hospital or pre-arranged accommodation. On Day 1, baseline clinical assessment and any outstanding diagnostics are completed: repeat ECG, TTE/TEE, coronary CTA or direct angiography, FFR/iFR measurement, ABI, blood workup including coagulation profile, renal function, and HbA1c. The Heart Team conducts a formal case conference to finalize the revascularization strategy (PCI vs. CABG vs. hybrid vs. medical optimization). Anesthesiology pre-assessment and patient consent discussions are completed on Day 2.

PHASE 3 — INTERVENTION (Day 2–5 Depending on Strategy):

For PCI: The procedure is performed in a state-of-the-art cardiac catheterization laboratory under local anesthesia with conscious sedation. Total procedure time is 45–120 minutes. IVUS or OCT is used to confirm optimal stent expansion. The patient is monitored in the post-cath recovery unit for 4–6 hours and transferred to a step-down unit or ward. For CABG: The patient is taken to the operating theater under general anesthesia. On-pump CABG requires 4–6 hours of operative time; off-pump (OPCAB) typically 3–5 hours. The patient is managed in the Cardiac ICU (CICU) for 24–48 hours post-operatively with hemodynamic monitoring, then transferred to a high-dependency unit (HDU).

PHASE 4 — ACUTE RECOVERY & HOSPITAL DISCHARGE (Day 3–10):

Post-PCI: Patients are mobilized on Day 1, oral feeding resumed immediately, and discharge planned for Day 2–3. Dual antiplatelet therapy (DAPT) is initiated with clear written instructions. Post-CABG: Chest physiotherapy, incentive spirometry, and early ambulation begin on post-operative Day 2. Mediastinal drains are removed on Day 2–3, and the patient transitions to a step-down room. Discharge occurs on Day 7–10 once wound healing, rhythm stability, and functional capacity milestones are met. Sternal precautions (no lifting >2 kg, no driving for 4–6 weeks) are reinforced.

PHASE 5 — IN-COUNTRY RECOVERY & REHABILITATION (Post-Discharge: 1–4 Weeks):

All patients remain in-country for a structured recovery period before clearance for international flight. Post-PCI patients typically require 7–14 days in-country, attending a follow-up clinic visit at Day 7 for wound check, ECG, and echocardiography. Post-CABG patients require 4–6 weeks in-country, attending structured outpatient cardiac rehabilitation sessions 3 times per week. GAF Healthcare arranges serviced apartment or hotel accommodation with attendant facilities within proximity to the treating hospital during this phase.

PHASE 6 — FIT-TO-FLY CLEARANCE & DISCHARGE DOCUMENTATION:

The treating cardiologist or cardiac surgeon issues a formal Fit-to-Fly Certificate upon confirming: stable hemodynamics, absence of active ischemia, healed surgical wound (for CABG), and no pleural effusion or pneumothorax. A comprehensive discharge summary including operative notes, drug-eluting stent specifications, conduit details (for CABG), post-procedural angiography images on CD, and a lifelong medication plan is provided. GAF Healthcare transmits all records digitally to the patient's home cardiologist for seamless continuity of care.

MILESTONES SUMMARY:

• Return to light activity (walking): 1–2 weeks post-PCI; 4–6 weeks post-CABG

• Return to sedentary work: 2 weeks post-PCI; 6–8 weeks post-CABG

• Return to moderate physical activity: 4–6 weeks post-PCI; 3 months post-CABG

• Resumption of driving: 1 week post-PCI (subject to local regulations); 6 weeks post-CABG

• Full cardiac rehabilitation completion: 3 months post-procedure